
Treatment with the BTK inhibitor BGB-3111 had an objective response rate (ORR) of 96% for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).

Treatment with the BTK inhibitor BGB-3111 had an objective response rate (ORR) of 96% for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).

The CD19-directed CAR T-cell therapy JCAR017 demonstrated a 60% complete response (CR) rate in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma.

D. Anda Norbergs, an oncologist based in Palm Harbor, Florida, has been indicted for purchasing unapproved cancer medications from foreign sources and defrauding Medicare, United States Attorney A. Lee Bentley, III has announced.

There has been renewed interest in eribulin mesylate (Halaven) following its FDA approval for advanced or unresectable liposarcoma and with the introduction of a growing body of preclinical work suggesting the agent has a novel anti–mesenchymal mechanism of action.

Findings of a recent randomized trial showed patients with myelofibrosis and thrombocytopenia had significantly greater reductions in spleen volume and symptoms when treated with the multikinase inhibitor pacritinib, compared with the best available therapy (BAT).

Higher levels of tumor-infiltrating lymphocytes (TILs) were associated with improvements in overall survival (OS) for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta).

Combining the PI3 kinase inhibitor TGR-1202 and ibrutinib (Imbruvica) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) demonstrated a high response rate without dose-limiting toxicities (DLTs).

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The next-generation BTK inhibitor acalabrutinib produced an objective response rate (ORR) of 38.1% as a monotherapy for patents with Richter transformation (RT), according to findings from the phase I/II ACE-CL-001 study presented at the 2016 ASH Annual Meeting.

James J. Hsieh, MD, discusses differential overall survival (OS) results of the RECORD-3 study based on 3 distinct mRCC molecular subgroups, classified by patients who harbored <em>BAP1</em> and/or <em>PBRM1</em> mutations.

Novel immunotherapy agents continue to move through the pipeline in the treatment landscape of bladder cancer, and they show no signs of slowing down.

The addition of the PD-L1 inhibitor atezolizumab (Tecentriq) to the MEK inhibitor cobimetinib (Cotellic) and the BRAF inhibitor vemurafenib (Zelboraf) induced a high response rate for patients with <em>BRAF</em>-mutant unresectable melanoma.

The FDA has expanded the approval for bevacizumab (Avastin) in ovarian cancer to include patients with platinum-sensitive recurrent disease as part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to Genentech, which developed the drug.

Regorafenib (Stivarga) demonstrates the first survival benefit in second-line setting for patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib, according to results of the phase III RESORCE trial published in <em>The Lancet</em>.

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. Mark Stein, MD, says that they can even serve as clinical endpoints in trials.

Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended.

While mouse models have historically been helpful in the research of immunotherapies, genetic testing and clinical models may play a role in the near future. These pre-clinical models have been criticized for some of their limitations, but Marcus Bosenberg, MD, PhD, confirms their current relevance and clinical applicability.<br />

Michael Morse, MD, discusses treatment considerations and options for 2 cases of patients with colorectal cancer

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) for use as a treatment for patients with refractory classical Hodgkin lymphoma.

Jeffery S. Weber, MD, PhD, discusses treatment considerations and options for 3 cases of patients with metastatic melanoma.

The FDA has granted a full approval and label update to ponatinib (Iclusig) for patients with chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Renowned oncologist Charles G. Drake, MD, PhD, has joined NewYork-Pesbyterian/Columbia University Medical Center (CUMC).

Researchers are currently investigating the use of tropomyosin receptor kinase (TRK) inhibitor entrectinib (RXDX-101) to treat patients with relapsed or refractory solid tumors or primary tumors of the central nervous system.

Breelyn Wilky, MD, recently sat down <em>Targeted Oncology</em> to discuss recent findings of a trial investigating axitanib and pembrolizumab in soft tissue sarcomas, as well as the role she envisions for immunotherapy in the treatment of sarcoma.

The European Commission has granted a conditional approval to ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma.

Findings of a new study revealed that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care (SOC) for the disease.

Robert A. Figlin, MD has been appointed the deputy director of the Integrated Oncology Service Line at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, recently sat down with <em>Targeted Oncology </em>to discuss his treatment decisions for 2 patient scenarios in prostate cancer.

Clinical trial findings from the past year will likely have a game-changing effect on the multiple myeloma landscape, according to Rafael Fonseca, MD.